Prognostic impact of KRAS and BRAFV600E mutations stratified by tumor site in resected stage III colon cancer patients treated with adjuvant mFOLFOX6 with or without cetuximab: NCCTG N0147 (Alliance).
Frank A. Sinicrope
No relevant relationships to disclose
Michelle R. Mahoney
No relevant relationships to disclose
Thomas C. Smyrk
No relevant relationships to disclose
Stephen N. Thibodeau
No relevant relationships to disclose
Richard M. Goldberg
Consultant or Advisory Role - Bayer (U); Jennerex Biotherapeutics (U); Sanofi (U)
Honoraria - Fresenius ; Yakult
Research Funding - Bayer; Sanofi
Garth D. Nelson
No relevant relationships to disclose
Daniel J. Sargent
No relevant relationships to disclose
Steven R. Alberts
No relevant relationships to disclose